Acute myeloid leukemia targets for bispecific antibodies

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

(2016) U. Reusch et al.   CLINICAL CANCER RESEARCH

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

Thymus: the next (re)generation

(2016) Mohammed S. Chaudhry et al.   IMMUNOLOGICAL REVIEWS

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics

(2016) Niloufar Ataie et al.   JOURNAL OF MOLECULAR BIOLOGY

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform

(2015) M. Al-Hussaini et al.   BLOOD

Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator

(2015) Han Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia

(2015) Hui Sun et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells

(2015) Charles J.M. Bell et al.   JOURNAL OF AUTOIMMUNITY

Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism

(2015) C Krupka et al.   LEUKEMIA

CD123 and its potential clinical application in leukemias

(2015) Keqiang Liu et al.   LIFE SCIENCES

A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells

(2015) Emily C Piccione et al.   mAbs

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia

(2015) Michael Durben et al.   MOLECULAR THERAPY

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

(2015) Tao Dao et al.   NATURE BIOTECHNOLOGY

Acute Myeloid Leukemia

(2015) Hartmut Döhner et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

(2015) Kimberly H. Harrington et al.   PLoS One

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Bispecific antibody releasing-mesenchymal stromal cell machinery for retargeting T cells towards acute myeloid leukemia blasts

(2015) R Aliperta et al.   Blood Cancer Journal

Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30

(2015) Christian Kellner et al.   OncoImmunology

The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells

(2015) Bo Yuan Huang et al.   PLoS One

A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

(2015) Marc Turini et al.   Oncotarget

Targeting Human C-Type Lectin-like Molecule-1 (CLL1) with a Bispecific Antibody for Immunotherapy of Acute Myeloid Leukemia

(2014) Hua Lu et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

(2014) S. Gill et al.   BLOOD

The past and future of CD33 as therapeutic target in acute myeloid leukemia

(2014) George S. Laszlo et al.   BLOOD REVIEWS

Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML

(2014) K. Blatt et al.   CLINICAL CANCER RESEARCH

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph

(2014) P. Carrega et al.   JOURNAL OF IMMUNOLOGY

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

(2014) Y. J. Yu et al.   Science Translational Medicine

Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemia

(2014) Roland B Walter   Expert Review of Hematology

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

A Chimeric Receptor with NKG2D Specificity Enhances Natural Killer Cell Activation and Killing of Tumor Cells

(2013) Y.-H. Chang et al.   CANCER RESEARCH

Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy

(2013) Y. Kienast et al.   CLINICAL CANCER RESEARCH

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2013) Wenli Zheng et al.   Clinical Lymphoma Myeloma & Leukemia

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses

(2012) Slava Stamova et al.   ANALYTICAL BIOCHEMISTRY

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

(2012) J. A. Pollard et al.   BLOOD

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia

(2012) M Hofmann et al.   LEUKEMIA

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

CD30 expression in acute myeloid leukemia is associated withFLT3-internal tandem duplication mutation and leukocytosis

(2012) Amir T. Fathi et al.   LEUKEMIA & LYMPHOMA

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

(2012) Christian Klein et al.   mAbs

HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1

(2012) Jeffrey M. Venstrom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

(2012) S.-R. Kuo et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia

(2011) Hiroto Yamazaki et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

(2011) Claire Roddie et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells

(2011) Marion Piedfer et al.   FASEB JOURNAL

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

(2011) S Stamova et al.   LEUKEMIA

A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting

(2011) Ingo Schubert et al.   mAbs

Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module

(2011) Slava Stamova et al.   MOLECULAR IMMUNOLOGY

High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia

(2011) Kai-Erik Witte et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (FcγRIII) expressed by human natural killer (NK) cells

(2010) Lucia M. R. Silla et al.   BRITISH JOURNAL OF HAEMATOLOGY

Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells

(2010) Christoph Stein et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Circulating CD33 and its clinical value in acute leukemia

(2010) Adam Abdool et al.   EXPERIMENTAL HEMATOLOGY

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Chemical generation of bispecific antibodies

(2010) V. R. Doppalapudi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody Internalization after Cell Surface Antigen Binding is Critical for Immunotoxin Development

(2009) Shu-Ru Kuo et al.   BIOCONJUGATE CHEMISTRY

A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma

(2009) M. P. Purdue et al.   BLOOD

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

(2009) Siddhartha Jaiswal et al.   CELL

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

(2009) Ravindra Majeti et al.   CELL

Soluble angiopoietin-2/sTie2 receptor ratio is an independent prognostic marker in adult acute myeloid leukemia

(2009) Salah Aref et al.   INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION

Monoclonal antibodies against IREM-1: potential for targeted therapy of AML

(2009) W Korver et al.   LEUKEMIA

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors

(2008) Johannes L Zakrzewski et al.   NATURE BIOTECHNOLOGY

The moonlighting enzyme CD13: old and new functions to target

(2008) Paola Mina-Osorio   TRENDS IN MOLECULAR MEDICINE